



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

October 25, 2022: 5:00 – 8:30 p.m.

- **Executive Session** **5:00 - 6:00**

- **Introductions and Approval of DUR Board Minutes** **6:00 - 6:05**
(Public Comment Prior to Board Action)

- **DVHA Pharmacy Administration Updates** **6:05 - 6:10**

- **Medical Director Update** **6:10 - 6:15**

- **Proposed 2023 DURB Meeting Schedule** **6:15- 6:20**

- **Follow-up Items from Previous Meetings** **6:20 - 6:20**
 - None at this time.

- **RetroDUR/ProDUR** **6:20- 6:30**
 - Introduce: Appropriate use of Asthma Controller Medications

- **Clinical Update: Drug Reviews** **6:30-6:45**
(Public comment prior to Board action)

Biosimilar Drug Reviews
 - None at this time.
Full New Drug Reviews
(Any new drug reviews that also fall within the Therapeutic Class Review (TCR) will be discussed during the Therapeutic Class Review)
 - None at this time.

- **New Managed Therapeutic Drug Classes** **6:45 - 6:45**
(Public comment prior to Board action)
 - None at this time.

- **Therapeutic Drug Classes – Periodic Review** **6:45 – 7:00**
(Public comment prior to Board action)
 - Cytokine/CAM Antagonists, including the following PDL categories:
 - Ankylosing Spondylitis
 - Cryoprin Associated Periodic Syndromes & Periodic Fever Syndrome
 - Gastrointestinal Biologics
 - Hidradenitis Suppurativa
 - Psoriasis Biologics
 - Rheumatoid, Juvenile, & Psoriatic Arthritis

- **Review of Newly Developed/Revised Criteria** **7:00 – 8:30**

(Public comment prior to Board action)

(All changes will be effective January 1, 2023)

- ADHD/Long-acting Methylphenidate
 - ADHD/Non-stimulant
 - Antibiotics/Inhaled
 - Anticonvulsants
 - Antidiabetics/GLP-1 RA (new drug review Mounjaro® (tirzepatide) included)
 - Antiretrovirals/Single Product Regimens
 - Carglumic Acid
 - Contraceptives/Patch
 - Cardiovascular/Heart Failure
 - GI/Bowel Evacuants
 - GNRH-LNRH Antagonists
 - Hemophilia Factor VIII/Extended Half-Life
 - Hematopoietics/Colony Stimulating Factors
 - Hematopoietics/ Erythropoietic Stimulating Agents
 - Hypoglycemia Treatments
 - MABS-Anti-IL, Anti-IgE (Immunologic Therapies for Asthma PDL Category) (new drug review Tezpire® (Tezepelumab-ekko) included)
 - Migraine Prophylaxis
 - Migraine Acute Treatment
 - Pituitary Suppressants-Central Precocious Puberty
 - Respiratory/Steroid Inhalers and Combinations
-
- **General Announcements** **8:30 – 8:30**
None at this time.
 - **Adjourn** **8:30**